跳至主要内容
临床试验/NCT03600168
NCT03600168Unknown不适用

A Multi-center, Single Arm Post-market Clinical Study to Confirm Safety and Performance of Purastat Absorbable Haemostatic Material for the Management of Bleeding After Open Liver Resection

3-D Matrix Europe SAS1 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2018年8月2日最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
80
试验地点
1
主要终点
Total Time-To-Haemostasis

研究概览

简要总结

The objective of this post-market clinical follow-up study is to collect medical information on patients implanted with PuraStat®, according to each participating institution's procedures and standards of care.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male or female patient ≥ 18 years old
  • Subject have been informed and understand the nature and extent of the study, agree to its provisions and have provided written approved informed consent
  • Patient undergoing elective primary or redo open liver resection for hepatic colorectal metastases with a curative intent
  • Subject, who, in the opinion of the Clinical Investigator, is able to understand this clinical study, cooperate with the study procedures and is willing to return for the required post-treatment follow-up.

排除标准

  • Known allergy or hypersensitivity to any component of the investigational treatment PuraStat®
  • Pregnant or interested in becoming pregnant during the duration of the study, or breast feeding
  • Concurrent participation in another clinical study with a medical device or medicinal product with interfering endpoints

结局指标

主要结局

Total Time-To-Haemostasis

时间窗: Intraoperatively

Total Time-To-Haemostasis will be intraoperatively measured (minutes, seconds)

次要结局

未报告次要终点

研究者

发起方
3-D Matrix Europe SAS
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Post-Market Clinical Study to Confirm Safety and... | 临床试验